PFE - Pfizer Inc.

NYSE - NYSE Delayed Price. Currency in USD
34.60
+0.99 (+2.95%)
At close: 4:02PM EDT

34.42 -0.18 (-0.52%)
Pre-Market: 7:00AM EDT

Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Outside Bar (Bearish)

Outside Bar (Bearish)

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close33.61
Open33.99
Bid34.42 x 3000
Ask34.58 x 800
Day's Range33.44 - 34.80
52 Week Range27.88 - 44.56
Volume23,768,203
Avg. Volume33,607,485
Market Cap191.948B
Beta (5Y Monthly)0.60
PE Ratio (TTM)12.07
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.52 (4.52%)
Ex-Dividend DateJan 29, 2020
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-15% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Yahoo Finance Presents: Senator Kirsten Gillibrand
    Yahoo Finance Video

    Yahoo Finance Presents: Senator Kirsten Gillibrand

    In this episode of Yahoo Finance Presents, Rick Newman speaks with New York Senator Kirsten Gillibrand about Congress' coronavirus relief bill and what lawmakers are doing to protect NY.

  • Pfizer says early studies of potential coronavirus treatment show promise
    Reuters

    Pfizer says early studies of potential coronavirus treatment show promise

    U.S. drugmaker Pfizer Inc said on Thursday that early data has helped it identify a drug candidate with the potential to help treat patients infected with the novel coronavirus. It also said it plans to support studies to determine whether existing Pfizer medicines, including its rheumatoid arthritis drug Xeljanz, may provide benefits for those struggling with the COVID-19 respiratory illness caused by the coronavirus. More than a dozen large drugmakers, including Pfizer, have announced plans in recent months to develop vaccines and treatments for the coronavirus, although few if any are likely to reach patients in time to stem the current outbreak.

  • Pfizer Stock Rises 3%
    Investing.com

    Pfizer Stock Rises 3%

    Investing.com - Pfizer (NYSE:PFE) Stock rose by 3.01% to trade at $34.61 by 15:30 (19:30 GMT) on Wednesday on the NYSE exchange.

  • Is AbbVie Stock A Buy Amid The Ongoing Coronavirus Pandemic?
    Investor's Business Daily

    Is AbbVie Stock A Buy Amid The Ongoing Coronavirus Pandemic?

    AbbVie stock initially fell on its $63 billion plan to buy Botox-maker Allergan, which helps the pharmaceutical company diversify as Humira patents expire. So, is ABBV stock a buy right now?

  • Biotech Stocks, ETFs to Gain on COVID-19 Vaccine & Drug Progress
    Zacks

    Biotech Stocks, ETFs to Gain on COVID-19 Vaccine & Drug Progress

    The race to introduce a vaccine and drug for COVID-19 is creating near-term opportunities, making the biotech sector a lucrative space for investments.

  • Pfizer's Upjohn Combo With Mylan Is Delayed — What That Means For PFE Stock
    Investor's Business Daily

    Pfizer's Upjohn Combo With Mylan Is Delayed — What That Means For PFE Stock

    Pfizer stock could see some gains in 2020 if it makes progress on a coronavirus vaccine with BioNTech. But its Upjohn merger with Mylan is now delayed. Is Pfizer stock a buy now?

  • Barrons.com

    Thousands of U.S. Factories Can Be Retooled to Fight Coronavirus, According to a New Survey

    The Moody’s unit 427 says it is in talks with local governments “who may or may not have the visibility on facilities.”

  • Reuters

    EU will avoid medicine shortage, industry chief says

    European Union countries will have access to the medicines they need to care for coronavirus sufferers, the bloc's industry chief Thierry Breton said on Thursday, adding pharmaceutical companies were doubling production to address shortages. The coronavirus pandemic has placed a huge strain on hospitals in Italy, Spain, France, and elsewhere in Europe as intensive care units fill up with tens of thousands of patients suffering the same illness. Hospital executives and doctors of nine European countries said in an open letter on Wednesday they only had up to two weeks worth of supplies of some medicines and urged greater European collaboration.

  • Biotech Stocks & ETFs to Gain on Progress in COVID-19 Vaccine Development
    Zacks

    Biotech Stocks & ETFs to Gain on Progress in COVID-19 Vaccine Development

    The rampant race to introduce a vaccine for the COVID-19 is creating near-term opportunities, making the biotech sector a lucrative space for investments.

  • Merck, Pfizer, Eli Lilly launch worker volunteer programs to aid in coronavirus fight
    American City Business Journals

    Merck, Pfizer, Eli Lilly launch worker volunteer programs to aid in coronavirus fight

    Major drugmakers Merck & Co. Inc.,, Pfizer Inc. and Eli Lilly and Co. are joining together to establish volunteer programs to enable employees who are licensed medical professionals to aid in the fight against COVID-19 while maintaining their base pay.

  • Pfizer (PFE) Stock Moves -0.03%: What You Should Know
    Zacks

    Pfizer (PFE) Stock Moves -0.03%: What You Should Know

    Pfizer (PFE) closed at $32.66 in the latest trading session, marking a -0.03% move from the prior day.

  • Bloomberg

    Pay a Bounty to Develop a Covid-19 Vaccine Faster

    (Bloomberg Opinion) -- If we want a vaccine or drug treatment to stop coronavirus, the government should ignore those complaining about drug-company profits and commit to a huge reward that encourages more businesses to develop one. It wouldn’t just save lives; it could save the global economy. The coronavirus could cost the U.S. $1.5 trillion in annual economic output, or $125 billion every month — and that’s a conservative estimate. The losses for the entire world economy will be four to five times larger. And these economic costs will be dwarfed by the human costs of illness and death. Absent a vaccine or treatment, this pandemic will likely be with us for more than a year. Speeding the development of vaccines and effective drug therapies by vastly increasing the rewards for businesses would decisively limit the economic damage. Based on the economic losses in the U.S. alone, the government should be willing to spend at least an additional $62.5 billion to spur Covid-19 research and development. Even if that shortened the crisis by just two weeks, it would be a bargain. Research teams at large pharma companies such as Roche, Eli Lilly, Sanofi Pasteur and Takeda, and smaller biotech firms such as BioNTech, are racing to develop a vaccine. But these firms stand to capture only a small fraction of the large economic benefit that will accrue to society when they successfully produce a vaccine or therapy. Developers will likely be pressured to offer a future vaccine at a low price. Even now, there have been calls to sharply limit future profits from such a vaccine. The result is significant underinvestment in the development of vaccines that will likely have large social benefits. Here is a simple way to see this. U.S. spending on all pharmaceutical R&D in 2020 was projected to be $80 billion — equivalent to three weeks of the annual U.S. economic output loss — with only a small fraction of this directed toward infectious diseases. In 1967, 26 pharmaceutical companies produced vaccines; by 1980, 17 did; only four — GlaxoSmithKline, Merck, Pfizer and Sanofi Pasteur — undertake significant production today. This is not surprising. Developing a vaccine requires $500 million to $1 billion in investment, recent estimates suggest, while only 7% of projects result in a vaccine. As a result, even today, with the pandemic raging, many small biotech firms are watching from the sidelines. Those working on vaccines rely on money from foundations and government initiatives. Two of the most promising developers of a Covid-19 vaccine, Inovio and Moderna, are funded by the Coalition for Epidemic Preparedness Innovations (Cepi), an alliance of charities and governments. The U.S. government, perhaps working with others, should guarantee a significant financial payment to whoever first develops a vaccine. One way to do this would be to commit to a high price for each administered dose of an effective vaccine or treatment therapy. As an example, if the U.S. government were to promise a price of $190 per administered dose to the developers, spending a maximum of $62.5 billion to vaccinate or treat all Americans, then society would have earned back its investment even if this only sped up the development by two weeks. The vaccine should also be made available at marginal cost to developing countries.The government could further stimulate collaboration by committing to large awards for successful clinical trials, provided that the research is fully disclosed. If the European Union were to make a similar commitment to this price per administered dose, the total incentives could be strengthened by another $100 billion. While creating vaccines always takes time, experts in the field have learned from previous episodes that there can be major bottlenecks in vaccine development and manufacturing. Once developed, the supply is likely to fall short of demand for a long period. Additional financial resources can relieve these production bottlenecks. We are not asking the U.S. government, or any other government, to pick winners. We are asking the government to make an ironclad commitment right now, backed by legislation, to reward those companies that successfully lead the fight against Covid-19 and future outbreaks.This column does not necessarily reflect the opinion of Bloomberg LP and its owners.Hanno Lustig is a professor of finance at Stanford University. Jeffrey Zwiebel is a professor of finance at Stanford University. For more articles like this, please visit us at bloomberg.com/opinionSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

  • GuruFocus.com

    US Indexes Close Higher Monday

    S&P; 500 up 3.35% Continue reading...

  • Barrons.com

    When Will a Coronavirus Vaccine be Ready? These 9 Programs Are Making Progress.

    There are currently at least 47 Covid-19 vaccine programs under way. Here are some to keep an eye on.

  • Mylan offers concessions to address EU concerns about Pfizer deal
    Reuters

    Mylan offers concessions to address EU concerns about Pfizer deal

    Generic drugmaker Mylan NV has offered concessions to address European Union antitrust concerns about its bid for Pfizer's off-patent branded drugs business Upjohn, a filing on the European Commission site showed on Monday. U.S. drugmaker Pfizer announced the deal in July as part of a strategy allowing it to focus on its more profitable newer medicines. The European Commission set an April 22 deadline for its decision after Mylan put in its offer on March 27.

  • Drug makers on shaky ground as clinical trials are postponed and drug launches delayed amid pandemic
    MarketWatch

    Drug makers on shaky ground as clinical trials are postponed and drug launches delayed amid pandemic

    Bristol-Myers Squibb Co.’s decision to hold off launching Zeposia, its newly approved multiple sclerosis treatment, underscores how disruptive the COVID-19 pandemic is to a trillion-dollar industry that relies heavily on collaborative working and meeting milestones that satiate investors.

  • GuruFocus.com

    Covid-19 Could Benefit Generic Drug Companies

    Pricing is increasing for makers of copycat medicines Continue reading...

  • Barrons.com

    Coronavirus Means Fewer Stock Buybacks, Analyst Says. It Could Shake Up Biopharma.

    As the government prepares to bail out industries amid the Covid-19 pandemic, stock buybacks are falling out of favor. One sector that does a lot of repurchases? The biopharma industry.

  • Barrons.com

    Pfizer and Mylan Postpone Upjohn Deal. Analysts Aren’t Worried.

    The news is the latest sign of the dramatic impact that the Covid-19 pandemic is having across the health care industry.

  • Zacks Value Trader Highlights: eBay, Pfizer, JPMorgan Chase, Intuitive Surgical and Edwards Lifesciences
    Zacks

    Zacks Value Trader Highlights: eBay, Pfizer, JPMorgan Chase, Intuitive Surgical and Edwards Lifesciences

    Zacks Value Trader Highlights: eBay, Pfizer, JPMorgan Chase, Intuitive Surgical and Edwards Lifesciences

  • Pfizer Stock Falls 3%
    Investing.com

    Pfizer Stock Falls 3%

    Investing.com - Pfizer (NYSE:PFE) Stock fell by 3.17% to trade at $30.68 by 09:30 (13:30 GMT) on Friday on the NYSE exchange.

  • 5 Superstar Stocks on Sale During the Coronavirus Crisis
    Zacks

    5 Superstar Stocks on Sale During the Coronavirus Crisis

    Stocks are the only thing people won't buy when they go on sale. But with stocks in a bear market, now's your chance to pick up some of the best companies.